Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype?
- PMID: 21340158
- DOI: 10.1590/s0004-27302010000800009
Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype?
Abstract
Noonan syndrome (NS) is an autosomal dominant disorder, with variable phenotypic expression, characterized by short stature, facial dysmorphisms and heart disease. Different genes of the RAS/MAPK signaling pathway are responsible for the syndrome, the most common are: PTPN11, SOS1, RAF1, and KRAS. The objective of this study was to report a patient with Noonan syndrome presenting mutations in two genes of RAS/MAPK pathway in order to establish whether these mutations lead to a more severe expression of the phenotype. We used direct sequencing of the PTPN11, SOS1, RAF1, and KRAS genes. We have identified two described mutations in heterozygosity: p.N308D and p.R552G in the genes PTPN11 and SOS1, respectively. The patient has typical clinical features similar to the ones with NS and mutation in only one gene, even those with the same mutation identified in this patient. A more severe or atypical phenotype was not observed, suggesting that these mutations do not exhibit an additive effect.
Similar articles
-
PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.J Hum Genet. 2008;53(11-12):999-1006. doi: 10.1007/s10038-008-0343-6. Epub 2008 Nov 20. J Hum Genet. 2008. PMID: 19020799
-
Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.Am J Med Genet A. 2011 Jun;155A(6):1217-24. doi: 10.1002/ajmg.a.33987. Epub 2011 May 5. Am J Med Genet A. 2011. PMID: 21548061
-
[SOS1 mutation: a new cause of Noonan syndrome].An Pediatr (Barc). 2008 Apr;68(4):365-8. doi: 10.1157/13117708. An Pediatr (Barc). 2008. PMID: 18394382 Spanish.
-
Update on the Clinical and Molecular Characterization of Noonan Syndrome and Other RASopathies: A Retrospective Study and Systematic Review.Int J Mol Sci. 2025 Apr 9;26(8):3515. doi: 10.3390/ijms26083515. Int J Mol Sci. 2025. PMID: 40332000 Free PMC article.
-
[Noonan syndrome: from phenotype to growth hormone therapy].Arq Bras Endocrinol Metabol. 2008 Jul;52(5):800-8. doi: 10.1590/s0004-27302008000500012. Arq Bras Endocrinol Metabol. 2008. PMID: 18797587 Review. Portuguese.
Cited by
-
RAS Proteins and Their Regulators in Human Disease.Cell. 2017 Jun 29;170(1):17-33. doi: 10.1016/j.cell.2017.06.009. Cell. 2017. PMID: 28666118 Free PMC article. Review.
-
RASopathy Cohort of Patients Enrolled in a Brazilian Reference Center for Rare Diseases: A Novel Familial LZTR1 Variant and Recurrent Mutations.Appl Clin Genet. 2022 Oct 21;15:153-170. doi: 10.2147/TACG.S372761. eCollection 2022. Appl Clin Genet. 2022. PMID: 36304179 Free PMC article.
-
In-Silico and In-Vitro Analysis of Human SOS1 Protein Causing Noonan Syndrome - A Novel Approach to Explore the Molecular Pathways.Curr Genomics. 2021 Dec 31;22(7):526-540. doi: 10.2174/1389202922666211130144221. Curr Genomics. 2021. PMID: 35386434 Free PMC article.
-
A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a PTPN11 mutation and a novel variant in SOS1.Am J Med Genet A. 2012 Jun;158A(6):1414-21. doi: 10.1002/ajmg.a.35363. Epub 2012 May 14. Am J Med Genet A. 2012. PMID: 22585553 Free PMC article.
-
Updated ACMG/AMP specifications for variant interpretation and gene curations from the ClinGen RASopathy expert panels.Genet Med Open. 2025 Apr 17;3:103430. doi: 10.1016/j.gimo.2025.103430. eCollection 2025. Genet Med Open. 2025. PMID: 40496714 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous